[2010] KECA 132 (KLR)

[2010] KECA 132 (KLR)

The Court found that the applicant's intended appeal was arguable, particularly on the points of whether the High Court improperly took judicial notice of facts and whether the similarity between the trade marks would actually cause confusion given the prescription-only nature of the drugs. The Court further held...

Source-derived case information.

Citation
[2010] KECA 132 (KLR)
Parties
Applicant: Syner-med Pharmaceuticals Ltd.; Respondent: Glaxo Group Limited
Court
Court of Appeal
Court Station
Court of Appeal at Nairobi
Jurisdiction
Kenya
Case Number
Civil Application 77 of 2010
Procedural Posture
Stay Application / Application for Stay of Execution Pending Appeal
Outcome
Stay of execution granted pending appeal.
Judges
CA Otieno
Legal Topics
Trade Mark Registration, Interlocutory Injunctions, Likelihood of Confusion, Judicial Notice, Balance of Convenience
Source Language
en
Intellectual Property Civil Procedure Trade Mark Registration Interlocutory Injunctions Likelihood of Confusion Judicial Notice Balance of Convenience

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 3 Authorities cited 3 Party arguments 2
Sign in to unlock

Parties

Syner-med Pharmaceuticals Ltd.

Applicant

Glaxo Group Limited

Respondent

Procedural Posture

Stay Application / Application for Stay of Execution Pending Appeal

  1. 1 Whether the applicant's intended appeal is arguable and not frivolous.
  2. 2 Whether refusal to grant a stay would render the intended appeal nugatory.
  3. 3 Whether the High Court erred in finding that 'SYNERCEF' is confusingly similar to 'ZINACEF'.

Ratio Decidendi

The Court found that the applicant's intended appeal was arguable, particularly on the points of whether the High Court improperly took judicial notice of facts and whether the similarity between the trade marks would actually cause confusion given the prescription-only nature of the drugs. The Court further held that refusal to grant a stay would likely render the appeal nugatory, as the applicant would be forced to withdraw or rebrand its product, causing significant disruption. The balance of convenience favoured maintaining the status quo by staying the High Court's judgment, allowing the applicant to continue marketing its product pending the outcome of the appeal, while holding the...

Court Disposition

Stay of execution granted pending appeal.

Orders

  • The judgment of the High Court dated 4th February, 2010 is stayed pending hearing and determination of the intended appeal.
  • The applicant's application for registration of the trade mark 'SYNERCEF' is held in abeyance pending the appeal.